CAPN7

Across TCGA pan-cancer cohorts, CAPN7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAPN7 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CAPN7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CAPN7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CAPN7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.958	0.620	.002	29	view →
HNSC	DFS	Quartile	II,III,IV	0.519	0.840	.006	11	view →
CCRCC	OS	Tertile	All	0.947	0.766	.011	9	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CAPN7–LUAD (DFS)

Open the LUAD breakdown →